Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 6, 2009

PerkinElmer Picks Up Analytica of Branford

  • PerkinElmer acquired Analytica of Branford, gaining insight and intellectual property in mass spectrometry (MS) and ion source technology. Analytica’s technology complements PerkinElmer’s human and environmental health portfolio.

    PerkinElmer will integrate Analytica’s current manufacturing operations into its Shelton, CT, facility. It will utilize the company’s existing Branford facility for R&D projects.

    “The acquisition of Analytica will allow us to offer our customers access to critical technologies such as time-of-flight and quadrupole mass spectrometers and new ion sources that provide more complete information as well as better throughput,” comments Richard Begley, Ph.D., president, Analytical Sciences, PerkinElmer.

    Past PerkinElmer Acquisitions
    PerkinElmer Acquires Arnel to Fortify Services for the Biofuels Industry (Dec. 3, 2008)
    PerkinElmer Offers $300M for ViaCell to Augment Neonatal Genetic Screening Business (Oct. 2, 2007)
    PerkinElmer Buys Thermal Analysis Product Line (Jan. 2, 2007)
    PerkinElmer Rounds Up Fifth Company for the Year (Dec. 21, 2006)
    PerkinElmer Secured Evotec’s HTS Division for $30.62M (Dec. 1, 2006)

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »